Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet Is Appointed to the Invizius Clinical Advisory Board

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Professor Peter Stenvinkel to its Clinical Advisory Board. Professor Stenvinkel is a world-renowned expert senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet (KI), Stockholm, Sweden.

Invizius is developing its H-Guard® Haemodialysis Priming Solution which comprises a novel protein that lines the inside of the dialysis filter and helps dialysis to take place undetected by the body’s immune system. This suppresses the blood’s foreign body response preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular and other complications.

A leading expert in the field of nephrology, Prof Stenvinkel has over 610 original publications and reviews and more than 30 book chapters on various aspects of inflammation, wasting and metabolism in chronic kidney disease patients (CKD). He has given more than 400 invited lectures at various international meetings and congresses in more than 30 different countries. He conducts translational research with a focus on risk factors for metabolic, cardiovascular and nutritional complications in CKD. Prof Stenvinkel has been on the Scientific Advisory Boards of AstraZeneca, Baxter, Fresenius Medical Care, Reata Pharmaceuticals and Vifor Pharma.

Richard Boyd, Chief Executive Officer of Invizius, said:

“Prof Stenvinkel is one of the world’s foremost authorities in nephrology and is focused on the translation of novel approaches into impactful treatments for renal patients. We are very privileged to have him join our Clinical Advisory Board. His expertise is particularly relevant to the work we are doing at Invizius and we look forward to his invaluable contributions as we accelerate the development of our programmes.”

Prof Peter Stenvinkel, Senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet, added: “Invizius has been founded on world-class research and I am very impressed by its H-Guard technology which has the potential to improve quality of life and safety of patients on dialysis. I am very pleased to begin working with the talented team developing novel and improved therapeutic approaches to improve the quality of life for this expanding patient group.”

Prof Peter Stenvinkel joins Invizius’ Clinical & Scientific Advisors, Professor Sandip Mitra (Manchester Royal Infirmary), and Professor Paul Barlow (University of Edinburgh).

Invizius recently announced it had been awarded two Innovate UK Biomedical Catalyst Grants to bring anti-inflammatory haemodialysis treatment to the clinic and to research peritoneal dialysis indication for its H-Guard® technology.


Read other executives on the move here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine